תבנית:תרופה/קפרלסה 300 מ"ג - Caprelsa 300 mg

×©××× ××Â !
××ª×¨××¤× × ×¢××× ×:××××¨ ××ª×¨××¤××ª ×©× ××©×¨× ×××¨××××ª.
×× ××ª×§××× ××××¢× ×¢× ××¤×¡×§×ª ×©××××§ ××ª×¨××¤× ×:××¢×¨××ª ×××××¢××ª ×¢× ××¤×¡×§×ª ×©××××§ ×ª×¨××¤××ª.
×ª××¨×× ×¢×××× ×××¨×× ××ª×¨××¤× ×× ××××§××ª×¨××¤××ª ××× 14/01/18.

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

××× ×× ×× × ××¡×¤××	×§×¤×¨××¡× 100 ×"× - Caprelsa 100 mg
×§×××¦× ×¤×¨××§××××××ª (ATC4)	L01EX Other protein kinase inhibitors
××¨××× ×¤×¢×× (ATC5)	Â Vandetanib 300MG âL01EX04
×¦××¨×ª ××ª×	×¤××× - PER OS
×¦××¨×ª ××× ××	××××××ª ××¦××¤××ª ×¤×××, FILM COATED TABLETS ××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××
××ª××××	Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision
×ª×× ××ª:× ×ª×× × ×¡×/×ª×¨××¤×/×§×¤×¨××¡× 300 ×"× - Caprelsa 300 mg
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	Â ××× ×¢××× ××¨××¤× Â

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
[ ×§×¤×¨××¡× 300 ×"×] ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	-
××××¢ ××¨×©×ª	-
×©× ××¦×¨×	GENZYME EUROPE B.V., NETHERLANDS
×©× ××¢× ××¨××©××	SANOFI - AVENTIS ISRAEL LTD
×¨××©×××	×ª××¨×× ×××©×: 05/2017. ×¨××©××× ××ª××¨××: 05/2017
×ª××¨×× ×¢×××× ×××¨××	14/01/18

××£ ×× × ××¦×¨ ×¢× ××× ××× ××××××¨ ×ª×× ××ª ×¢× ×¤×¨×× ××ª×¨××¤×.

{{×ª×¨××¤×/×§×¤×¨××¡× 300 ×"× - Caprelsa 300 mg}}

×:

{{×ª×¨××¤×/×§×¤×¨××¡× 300 ×"× - Caprelsa 300 mg
| ×©× ××¤×¨×××¨=×¢×¨× ×××© (×××¨×¡ ××ª ××¢×¨× ×©×××× ×××××¨)
}}

השינוי האחרון נעשה בֹ־23 בספטמבר 2025 ב־07:04

ויקיתרופות